Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.36 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150950 | 0.81 | HSP90AA1 (0.44) | PARP1MEN1KMT2ADRD2PDCD1LG2 | |
| SCHEMBL2955892 | 0.80 | PARP1 (0.54) | PARP1PARP2PARP3 | |
| SCHEMBL5156518 | 0.78 | PARP1 (0.40) | PARP1MEN1KMT2ASCN4ACHRM2 | |
| SCHEMBL27570265 | 0.76 | MEN1 (0.44) | PARP1MEN1KMT2ACHRM2CHRM5 | |
| SCHEMBL27463457 | 0.76 | HSP90AB1 (0.49) | MEN1KMT2ACHRM2CHRM5CHRM3 | |
| SCHEMBL22721015 | 0.75 | HTR2C (0.54) | MEN1KMT2ASCN4ACHRM2CHRM5 | |
| SCHEMBL31648194 | 0.75 | HTR2C (0.54) | MEN1KMT2ASCN4ACHRM2CHRM5 | |
| SCHEMBL24073689 | 0.74 | PARP1 (0.42) | PARP1MEN1KMT2ACHRM2CHRM5 | |
| Hydrochloric Acid SCHEMBL31648881 | 0.73 | HTR2C (0.56) | MEN1KMT2ASCN4ACHRM2CHRM5 | |
| SCHEMBL13751425 | 0.73 | MEN1 (0.41) | MEN1KMT2APDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | claimed |
| EP-2170820-A2 | IMPROVED PROCESS OF AMIDE FORMATION | Glaxo Group Limited (GB) | 2010-04-07 | — | — | EP | claimed |
| WO-2008155334-A2 | IMPROVED PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | claimed |
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| EP-2170820-A2 | IMPROVED PROCESS OF AMIDE FORMATION | Glaxo Group Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| EP-2170820-A2 | IMPROVED PROCESS OF AMIDE FORMATION | Glaxo Group Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155334-A3 | IMPROVED PROCESS OF AMIDE FORMATION | GLAXO GROUP LTD (GB) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008155334-A2 | IMPROVED PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155334-A2 | IMPROVED PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | ADH1C, ADH5, ADH1A | PARP1 498/4885MEN1 3549/4885KMT2A 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.